DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report issued to clients and investors on Friday. The firm set a “hold” rating on the stock.

Several other equities analysts have also recently issued reports on DBVT. JMP Securities reaffirmed a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a research note on Friday, January 10th. HC Wainwright lifted their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th.

DBV Technologies Stock Down 2.7 %

NASDAQ:DBVT opened at $4.73 on Friday. The business’s 50-day moving average price is $3.38 and its 200 day moving average price is $3.83. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $9.49. The firm has a market cap of $97.29 million, a P/E ratio of -1.05 and a beta of 0.64.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.